Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA approves Biogen...

    FDA approves Biogen drug for lead genetic cause of infant death

    Written by supriya kashyap kashyap Published On 2016-12-25T11:05:09+05:30  |  Updated On 25 Dec 2016 11:05 AM IST
    FDA approves Biogen drug for lead genetic cause of infant death

    The U.S. Food and Drug Administration said it has approved Biogen Inc's drug to treat spinal muscular atrophy, the leading genetic cause of death in infants.


    It is the first FDA-approved medicine for spinal muscular atrophy, a devastating disease that affects about one in 10,000 live births.


    The drug, nusinersen, which was discovered by Ionis Pharmaceuticals and licensed to Biogen, will be sold under the brand name Spinraza. The FDA approved it for use across the full range and severity of the disease.


    Dr. Billy Dunn, director of the FDA's division of neurology products, said the agency "could not be more pleased to have the first approved treatment for this debilitating disease."


    In the most severe form of spinal muscular atrophy, known as type 1, or infantile SMA, babies rarely make it to their second birthday.


    Annual Spinraza sales could reach $2 billion, according to RBC Capital Markets analyst Michael Yee.


    Spinraza will be the first major drug launch under Biogen's new chief executive, Michel Vounatsos, who will replace George Scangos on Jan. 6.


    SMA is caused by deficiency of a protein called smn in the spinal motor neurons. It leads to severe and progressive muscular atrophy and weakness, including in muscles needed for breathing and swallowing. Spinraza, which is injected into the spinal fluid, increases levels of the deficient protein.


    In clinical trials, nusinersen led to dramatic improvement in motor milestones and extended survival.


    It has been tested with successful results in all severities of the disease, including in infants with the genetic deficiency who have yet to show symptoms of the disease, Biogen said.


    Type 2, or childhood onset SMA, affects toddlers and children. Even the least severe form, type 3 SMA, can be disabling as it progresses, leaving people needing wheelchairs, Biogen said.


    There are only about 9,000 patients living in the United with SMA. Those numbers are likely to rise with an effective treatment that helps children to live longer.

    BiogenDr Billy Dunninfant deathIonisSpinrazaUS Food & Drug AdministrationUSFDA
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok